Document:

EX-10.23

 Exhibit 10.23 

 
 

 
 April 2, 2019 
 Richard
Scheller 
 Sent Via Email 
 Re: BridgeBio Services
Employment 
 Dear Richard: 
 BridgeBio Services, Inc. (the
“Company”) is pleased to offer you employment as Senior Advisor, Chairman of R&D. With powers, duties, responsibilities, and accountabilities as set forth below and in the job description for the position, or as may from time to time
be prescribed by the Company’s senior executives or the Board of Directors of the Company (the “Board”), provided that such duties are consistent with your position, In your role, you would also act as a Management Committee Advisor.

 The position is a part-time, exempt position and you will be required to devote 40% of your full working time and efforts to the business and affairs of
the Company. By signing this letter agreement, you confirm to the Company that you have no contractual commitments or other legal obligations that would prohibit you from performing your duties for the Company. 

The Company will pay you a starting salary beginning as of your start date at the annual rate of $500,000.00, payable in accordance. with the Company’s
standard payroll schedule and subject to tax-related deductions and withholdings. This salary will be subject to adjustment pursuant to the Company’s employee compensation policies in effect from time to time. In addition, The Company will
grant you stock options in an amount to be determined but prior to any public offering. 
 You will be eligible to participate in or receive benefits under
the Company’s employee benefit plans in effect from time to time (including, without limitation, any group health care plan, Paid Time Off, and 401(k)), subject to the terms of such plans. 

It is understood that you are an “at-will” employee. You are not being offered employment for a definite
period of time, and either you or the Company may terminate the employment relationship at any time and for any reason, with or without cause or prior notice and without additional compensation to you. Any contrary representations that may have been
made to you are superseded by this letter agreement. Although your job duties, title; reporting relationship, compensation and benefits, as well as the Company’s personnel policies and procedures, may change from time to time (except as
otherwise provided herein), the “at will” nature of your employment may only be changed in an express written agreement signed by you and a duly authorized officer of the Company (other than you). 

Like all Company employees, you will be required, as a condition of your employment with the Company, to sign the Company’s standard Proprietary
Information and Inventions Agreement (the “Confidentiality Agreement”), a copy of which is attached hereto as Exhibit A. 

  
 421 Kipling Street, Palo
Alto, CA 94301 

 

 
  

 This offer is contingent upon a background check clearance, reference check, and satisfactory proof of your
right to work in the United States. You agree to assist as needed and to complete any documentation at the Company’s request to meet these conditions. 

The Immigration Reform and Control Act requires employers to verify the employment eligibility and identity of new employees. You will be required to complete
a Form 1-9 which will be provided to you before your start date. Please bring the appropriate documents listed on that form with you when you report for work. We will not be able to employ you if you fail to
comply with this requirement. Also, this offer is subject to satisfactory reference checks if necessary. 
 This letter agreement and the Confidentiality
Agreement constitute the complete agreement between you and the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, representations or understandings (whether written, oral or implied) between
you and the Company. This letter agreement may not be amended or modified, except by an express written agreement signed by both you and a duly authorized officer of the Company, although your job, duties, title, reporting relationship, compensation
and benefits may change from time to time. 
 We hope that you will accept our offer to join the Company. You may indicate your agreement with these terms
and accept this offer by signing and dating both the enclosed duplicate original of this letter agreement and the enclosed Confidentiality Agreement and returning them to me. This offer, if not accepted, will expire at the close of business on April
12. Should you accept this offer, your start date of employment will be retroactive to January 1, 2019 or any other date agreed upon between you and the Company. 
  

	
	Sincerely,
	
	 /s/ Neil Kumar

	Neil Kumar and the BridgeBio Team
	
	I have read and accept this employment offer.
	
	 /s/ Richard Scheller

	Richard Scheller

 April 5, 2019 
 Date

  
 421 Kipling Street, Palo
Alto, CA 94301EX-10.24

 Exhibit 10.24 

 
 

 
 March 22, 2016 

Dr. Henderson 
  

	Re:	 BridgeBio Employment 

Dear Michael: 
 BridgeBio LLC (the “Company”) would be
lucky to have you on board as VP of Asset Acquisition, Strategy, and Operations (title to be agreed upon with you). As an outstanding performer in both the science and business realms, you bring critical perspectives that would immediately increase
the value of BridgeBio and positively impact our ability to help the patients we serve. 
 In your role, you would: 

 

	 	•	 	 Work with senior management and the BOD to identify and acquire stakes in attractive genetic disease assets

  

	 	•	 	 Work with the BOD and senior management to help formulate and communicate a compelling vision and strategic
direction and value creation plan for the company 

  

	 	•	 	 Help develop and maintain strategic partnerships with external companies, overseeing critical activities

  

	 	•	 	 Serve as a spokesperson for company, establishing and communicating the company’s image, and enhancing its
visibility among potential partners 

  

	 	•	 	 Help to ensure that qualified personnel are attracted and retained 

 

	 	•	 	 Represent, when appropriate, BridgeBio in scientific conferences, presentations, industry and investment groups

  

	 	•	 	 Build and maintain solid working relationships with key opinion leaders and investors 

 

	 	•	 	 Foster an internal atmosphere that supports individual accountability, transparency, open communication and
respect to enable employees to focus on the Company’s mission 

 Your effective date of hire (the “Start Date”) will be
whenever you would like in Q1/Q2 of 2016. 
 Your compensation for this position will be at the rate of $200,000 per year. There is no bonus program in the
company as of yet, but as soon as there is, you will be a part of that. Finally, we 

 
would grant you an option to purchase 50,000 shares of the Company’s Interest. The exercise price of the Option will be at least equal to the fair market value of the Company’s common
stock on the date of grant, and the Board of Directors may elect to seek a third party valuation of such fair market value, which could delay the date that the Option is granted. The Option will be subject to the terms and conditions of the
Company’s then-current stock option plan and form of stock option agreement. These options will vest as follows: 1/60th of the shares will vest on a monthly basis, such that 100% of such
Common Units shall be vested on the 5 year anniversary. We will give you a one-time bonus as well to cover the cost of early exercise on this option. 

It is understood that you are an “at-will” employee. You are not being offered employment for a definite
period of time, and either you or the Company may terminate the employment relationship at any time and for any reason, with or without cause or prior notice and without additional compensation to you. 

In making this offer, the Company understands that you are under no obligation to other current employers that might impair the performance by you of your
duties as an employee of the Company. 
 The Immigration Reform and Control Act requires employers to verify the employment eligibility and identity of new
employees. You will be required to complete a Form I-9 which will be provided to you before the Start Date. Please bring the appropriate documents listed on that form with you when you report for work. We will not be able to employ you if you fail
to comply with this requirement. Also, this offer is subject to satisfactory reference checks if necessary. 
 This letter agreement will accompany a
BridgeBio Management LLC agreement – these two documents together constitute the complete agreement between you and the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, representations or
understandings (whether written, oral or implied) between you and the Company. This letter agreement may not be amended or modified, except by an express written agreement signed by both you and a duly authorized officer of the Company, although
your job duties, title, reporting relationship, compensation and benefits may change from time to time. 
 Sincerely, 

/s/ Neil Kumar 
 Neil Kumar and the BridgeBio Team 

I, Michael Henderson, accept the offer terms proposed by Neil Kumar and the BridgeBio team. 

 

	
	 /s/ Michael Henderson

	Michael Henderson

 

 
 May 1, 2017 
 Michael T.
Henderson 
  

	 	Re:	 Transfer of Employment 

Dear Michael: 
 As you may know, BridgeBio Pharma
LLC (the “Company”) is in the process of transferring all of its operating assets into separate corporate entities (the “Restructuring”). As part of the Restructuring, all Company employees are being transferred to
BridgeBio Services, Inc. (“BridgeBio Services”), a newly formed subsidiary of the Company. Consequently, effective as of May 1, 2017 (the “Transfer Date”), your employment will be transferred to BridgeBio
Services on an at-will basis, and you will no longer be employed by the Company. Except as otherwise described below, the terms and conditions of your employment will remain the same. 

Payroll. Following the Transfer Date, you will be paid at the same rate and on the same schedule as before the Transfer Date, but
BridgeBio Services will begin issuing your paychecks using its Employer Identification Number. Credit for all employment taxes paid by you and the Company prior to the Transfer Date will be transferred to BridgeBio Services without any additional
action on your part. 
 Health and Welfare Benefits. Following the Transfer Date, you will be eligible to participate in an upgraded
Platinum health and welfare benefit plan than which you are currently eligible to participate, subject to their terms and conditions. You have already completed new enrollment forms, and have been informed you will not be credited for amounts you
have paid toward any deductibles and out-of-pocket maximums during the plan year prior to the Transfer Date (such amounts, the “Deductibles”). In order
to compensate for the loss of such credit, BridgeBio Services will make a cash payment to you in an amount equal to the Deductibles plus 35% which is an estimate equal to the aggregate withholding and employment taxes due by you in connection with
the Deductibles and the additional amount, such payment to be made by the end of May provided you include an EOB to support the deductible amount met to date 

Management Incentive Units. Any Management Incentive Units (“MIUs”) previously granted to you will remain outstanding
and eligible to vest in accordance with their terms, provided that, upon your signature below, the agreement(s) evidencing your MIUs will be deemed amended to provide that your MIUs will vest based upon your continued employment with BridgeBio
Services. The terms and conditions of your MIUs will otherwise remain the same. 
 Accrued PTO. In connection with your transfer of
employment, your accrued and unused vacation days and paid time off (collectively, “Accrued PTO”) will be transferred to BridgeBio Services, and you will be entitled to use your Accrued PTO in accordance with the same policies in
effect prior to the Transfer Date. By signing this letter, you consent to the foregoing transfer of Accrued PTO to the extent necessary. 

Please indicate your agreement to the foregoing by signing in the space provided below and returning it to Lena Pang or Kristie Dang by
May 5, 2017. Should you have any questions regarding your transfer of employment, please contact Asha Rajagopal at asha@solutions-on-call.com. 

 
			
	Sincerely,
	
	BRIDGEBIO PHARMA LLC
		
	By:	 	 /s/ Neil Kumar

	Name:	 	Neil Kumar
	Title:	 	CEO

  

					
	ACCEPTED AND AGREED,
	this	 	 May 5, 2017
	 	.
	
	 /s/ Michael Henderson

	Michael T. Henderson

  
 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]